Online inquiry

IVTScrip™ mRNA-Human ARHGEF11, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK26808MR)

This product GTTS-WK26808MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ARHGEF11 protein. This product can be used in Ciliated epithelial cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_001377418.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 9826
UniProt ID O15085
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ARHGEF11, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK26808MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK13711MR IVTScrip™ mRNA-Human ADAP2, (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ADAP2
GTTS-WK27181MR IVTScrip™ mRNA-Human ARRDC3-AS1, (Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ARRDC3-AS1
GTTS-WK22104MR IVTScrip™ mRNA-Human ASCC3, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ASCC3
GTTS-WK15227MR IVTScrip™ mRNA-Human ANKRD45, (Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ANKRD45
GTTS-WK27395MR IVTScrip™ mRNA-Human ARHGAP30, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARHGAP30
GTTS-WK14603MR IVTScrip™ mRNA-Human ANKRD17, (Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ANKRD17
GTTS-WK14258MR IVTScrip™ mRNA-Human ACTC1, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACTC1
GTTS-WK24727MR IVTScrip™ mRNA-Human ARID5A, (Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ARID5A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW